Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for Fulcrum Therapeutics (FULC) over the last 4 years, with Sep 2025 value amounting to $100,000.

  • Fulcrum Therapeutics' Gains from Investment Securities fell 99.07% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 75.81%. This contributed to the annual value of $9.4 million for FY2024, which is 6.19% down from last year.
  • Fulcrum Therapeutics' Gains from Investment Securities amounted to $100,000 in Q3 2025, which was down 50.00% from $200,000 recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Gains from Investment Securities registered a high of $12.3 million during Q1 2024, and its lowest value of $100,000 during Q2 2021.
  • Moreover, its 3-year median value for Gains from Investment Securities was $6.9 million (2023), whereas its average is $5.8 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 2,100.00% in 2022, then crashed by 99.07% in 2025.
  • Quarterly analysis of 5 years shows Fulcrum Therapeutics' Gains from Investment Securities stood at $500,000 in 2021, then surged by 104.45% to $5.9 million in 2022, then soared by 359.75% to $10.1 million in 2023, then crashed by 99.01% to $10.7 million in 2024, then crashed by 99.07% to $100,000 in 2025.
  • Its Gains from Investment Securities was $100,000 in Q3 2025, compared to $200,000 in Q2 2025 and $10.7 million in Q3 2024.